← Pulse/Companies

Jupiter Neurosciences on Pulse

Biotech

The full thread of our Jupiter Neurosciences coverage — a running record of every development we've tracked, with the VC take on each.

2
Stories
2
With a headline figure
Jun 26, 2026
Date

Coverage Timeline

newest first
  1. IPOJupiter Neurosciences Files S-1 to Fund Its Neuroinflammation and Longevity Pipeline→
  2. IPOJupiter Neurosciences Files an S-1 as It Pushes JOTROL Into Parkinson's Trials→

All Coverage

IPOS-1 filed

Jupiter Neurosciences Files S-1 to Fund Its Neuroinflammation and Longevity Pipeline

Clinical-stage biotech Jupiter Neurosciences (Nasdaq: JUNS) filed a Form S-1 with the SEC to register fresh capital as it advances its lead candidate JOTROL, a proprietary resveratrol platform targeting rare and neuroinflammatory CNS disorders and, increasingly, longevity. The filing adds another central-nervous-system name to a 2026 biotech pipeline that keeps widening alongside AI and chips.

Jun 26, 2026
IPOS-1 filed

Jupiter Neurosciences Files an S-1 as It Pushes JOTROL Into Parkinson's Trials

Clinical-stage biotech Jupiter Neurosciences (Nasdaq: JUNS) filed a Form S-1 with the SEC to register additional capital as it advances JOTROL, its enhanced resveratrol formulation, into a Phase 2a Parkinson's disease trial. The filing adds a CNS-focused name to a 2026 capital-markets pipeline that biotech is increasingly populating alongside AI and chips.

Jun 26, 2026